Please use this identifier to cite or link to this item:
|Title:||Commentary: Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications||Authors:||Cao, T.
|Issue Date:||2005||Citation:||Cao, T.,Heng, B.C. (2005). Commentary: Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications. Annals of Clinical and Laboratory Science 35 (3) : 227-229. ScholarBank@NUS Repository.||Abstract:||Currently there are two technology platforms for the ablation of protein function: (a) RNAi-mediated gene-silencing at the post-transcriptional level, and (b) intrabody knockout of protein function at the post-translational level. Both approaches hold much promise for therapeutic applications. The pertinent question is how to choose between these alternative approaches. This commentary examines the advantages and disadvantages of these newly-emerging technology platforms. The RNAi approach is much less technically challenging than the intrabody-mediated knockout of protein function, but its major limitation is non-specificity. Although it is time-consuming and labor-intensive to generate intrabodies for specific intracellular protein targets, a much higher level of specificity can be attained. Ultimately, the choice between these strategies depend on the specific application in question, as well as on further technical advances in both technology platforms. © 2005 by the Association of Clinical Scientists, Inc.||Source Title:||Annals of Clinical and Laboratory Science||URI:||http://scholarbank.nus.edu.sg/handle/10635/47124||ISSN:||00917370|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 14, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.